SCHEMBL29700993

SCHEMBL29700993

Cc1nccc(Nc2cc(-c3cc(-c4cccnc4C(F)(F)F)[nH]c(=O)c3)ccn2)n1

nearest known ligand 0.60

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 20/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22655427 1.00 PIK3C3 (0.60) PIK3C3
SCHEMBL29701003 0.88 PIK3C3 (0.77) PIK3C3
SCHEMBL20765374 0.88 PIK3C3 (0.77) PIK3C3
SCHEMBL24469444 0.85 PIK3C3 (0.56) PIK3C3
SCHEMBL20765764 0.82 PIK3C3 (0.63) PIK3C3
SCHEMBL29700998 0.82 PIK3C3 (0.63) PIK3C3
SCHEMBL29700996 0.82 PIK3C3 (0.63) PIK3C3
SCHEMBL29701008 0.82 PIK3C3 (0.63) PIK3C3
SCHEMBL20765384 0.82 PIK3C3 (0.51) PIK3C3
SCHEMBL29700999 0.82 PIK3C3 (0.51) PIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384180-A1 COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER Deciphera Pharmaceuticals, LLC (US) 2024-06-19 EP claimed
CN-118201619-A Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer 德西费拉制药有限责任公司 2024-06-14 CN claimed
CN-117255686-A Antiviral activity of VPS34 inhibitors 德西费拉制药有限责任公司 2023-12-19 CN claimed
EP-4251163-A1 ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS Deciphera Pharmaceuticals, LLC (US) 2023-10-04 EP claimed
CN-111094271-B Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds 思普瑞特生物科学公司 2023-02-28 CN claimed
WO-2023019259-A1 COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER DECIPHERA PHARMACEUTICALS, LLC (US) 2023-02-16 WO claimed
EP-3672948-B1 PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2022-10-05 EP claimed
WO-2022115546-A1 ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS DECIPHERA PHARMACEUTICALS, LLC (US) 2022-06-02 WO claimed
EP-4384180-A1 COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER Deciphera Pharmaceuticals, LLC (US) 2024-06-19 EP disclosed
CN-118201619-A Combination therapy of VPS34 inhibitors with STING agonists for the treatment of cancer 德西费拉制药有限责任公司 2024-06-14 CN disclosed
CN-117255686-A Antiviral activity of VPS34 inhibitors 德西费拉制药有限责任公司 2023-12-19 CN disclosed
EP-4251163-A1 ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS Deciphera Pharmaceuticals, LLC (US) 2023-10-04 EP disclosed
CN-116041321-A Pyridinamine-pyridone compounds and pyrimidinamine-pyridone compounds 思普瑞特生物科学公司 2023-05-02 CN disclosed
CN-116041320-A Pyridinamine-pyridone compounds and pyrimidinamine-pyridone compounds 思普瑞特生物科学公司 2023-05-02 CN disclosed
CN-111094271-B Pyridinamine-pyridinone compounds and pyrimidinamine-pyridinone compounds 思普瑞特生物科学公司 2023-02-28 CN disclosed
WO-2023019259-A1 COMBINATION THERAPY OF VPS34 INHIBITORS AND STING AGONIST FOR USE IN THE TREATMENT OF CANCER DECIPHERA PHARMACEUTICALS, LLC (US) 2023-02-16 WO disclosed
EP-3672948-B1 PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS SPRINT BIOSCIENCE AB (SE) 2022-10-05 EP disclosed
WO-2022115546-A1 ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS DECIPHERA PHARMACEUTICALS, LLC (US) 2022-06-02 WO disclosed